Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Reactie op opkomende antimicrobiële resistentie met Containment Microbiota Therapy (REACT)

3 november 2026 bijgewerkt door: Michael Woodworth, Emory University

Reactie op opkomende antimicrobiële resistentie met inperking van microbiotatherapie

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

Studie Overzicht

Gedetailleerde beschrijving

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO) in patients admitted to long-term care facilities. REACT is designed to test the safety and efficacy of instillation of donor intestinal microbiota.

Patients admitted to long-term care facilities (e.g. long-term acute care hospitals and ventilator-capable skilled nursing facilities) found to be MDRO colonized during prevalence screening activities performed in the related APPS study.

Facilities undergo prevalence sampling that involves participant peri-rectal, inguinal, and stool sampling to estimate the prevalence of targeted MDROs (CRE, ESBL, VRE, MDRP) under the accompanying APPS protocol. Patients who are positive with at least one targeted MDRO are eligible for an Emory manufactured MT product (via rectal enema or feeding tube), or observation followed by repeat sampling at Days 7, 14, 21, and 28. Participants will be followed with collection of data on adverse events/safety/changes in medications at Days 0, 7, 14, 21, 28, and followed up once a month for 6 months, after MT administration.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

58

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30329
        • A.G Rhodes Wesley Woods
      • Decatur, Georgia, Verenigde Staten, 30030
        • Emory Long Term Acute Care (LTAC)
    • Illinois
      • Hinsdale, Illinois, Verenigde Staten, 60521
        • RML Specialty Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19146
        • Penn Medicine Rittenhouse

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document.
  2. Be at least 18 years old at the time of consent.
  3. Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up.
  4. Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol).
  5. Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28.
  6. The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  7. Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).

Exclusion Criteria:

  1. Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP.

  2. Have known uncontrolled intercurrent illness(es):

    1. Symptomatic congestive heart failure
    2. Acute coronary syndrome
    3. Cardiac arrhythmia
    4. Untreated in-situ colorectal cancer
    5. Toxic megacolon
    6. Ileus
    7. Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens).
    8. other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable.
  3. Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1.

  4. Have a compromised immune system, defined as:

    1. AIDS with CD4+ T-cell count <200 and detectable HIV viral load on most recent assay.
    2. Absolute neutrophil count (ANC) <1,000 neutrophils / mL on day of enrollment.
    3. Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment.
    4. History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
  5. Have a history of significant food allergy that led to anaphylaxis or hospitalization.

  6. Have a life expectancy of 24 weeks or less

  7. Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:

    1. Known active intravenous drug or alcohol abuse
    2. Uncontrolled psychiatric illness
    3. Social situations (e.g. incarceration)
  8. Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Group 1: microbiota therapy (MT)

Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition).

Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.

Andere namen:
  • Fecale microbiota-transplantatie (FMT)
  • Microbioom therapeutisch (MT)
  • Ontlasting van gezonde donoren in zoutoplossing met 9% glycerol per volume
Geen tussenkomst: Group 2: Observation

Group 2 will be assigned to observation.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Difference in number of solicited Adverse Events (AEs)
Tijdsspanne: Day 0, Day 7 post-intervention

Difference in number of solicited AEs between Day 0 and Day 7 in AMG-treated vs Observation participants.

Day 0, Day 7 post-intervention
Difference in severity of solicited AEs
Tijdsspanne: Day 0, Day 7 post-intervention

Difference in severity of solicited AEs will be compared in AMG-treated vs Observation participants. Graded as mild, moderate or severe, up to 7 days post-intervention.

Day 0, Day 7 post-intervention
Difference in number of unsolicited AEs
Tijdsspanne: Day 0, Day 28 post-intervention

Difference in number of unsolicited AEs between Day 0 and Day 28 in AMG-treated vs Observation participants.

Day 0, Day 28 post-intervention
Difference in severity of unsolicited AEs
Tijdsspanne: Day 0 and Day 28

Difference in severity of unsolicited AEs will be collected between Day 0 and Day 28. Graded as mild, moderate or severe and compared in AMG-treated vs Observation participants

Day 0 and Day 28
Number of participants by composite MDRO Colonization and survival status
Tijdsspanne: Day 28 post-intervention

Participants will be classified into one of three ordinal categories: (1) alive without MDRO colonization, (2) alive with MDRO colonization, or (3) deceased. MDRO colonization is defined as a stool culture at Day 28 positive for any target multidrug-resistant organism (MDRO).

Day 28 post-intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Count of serious AEs (SAEs)
Tijdsspanne: Day 180 (6 months)

Count of serious AEs (SAEs) between Day 0 and Month 6 (Day 180) censored by last telephone visits or death, whichever is later.

Day 180 (6 months)
Count of AEs of Special Interest (AESIs)
Tijdsspanne: Day 180 (6 months)

Count of AEs of Special Interest (AESIs) at day Day 180, censored by last telephone visit or death, whichever is later.

Day 180 (6 months)
Number of participants by category-specific MDRO Colonization and survival status
Tijdsspanne: Day 28

Participants will be classified into one of three ordinal categories: (1) survival without colonization of the category-specific multidrug-resistant organism (MDRO), (2) survival with colonization of the category-specific MDRO, or (3) deceased. Category-specific MDRO colonization is defined as a stool culture at Day 28 positive for the category-specific MDRO being evaluated (e.g., ESBL, CRE, MDRP, or VRE).

Day 28

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Michael Woodworth, MD, Emory University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 januari 2025

Primaire voltooiing (Werkelijk)

8 juli 2026

Studie voltooiing (Geschat)

1 januari 2027

Studieregistratiedata

Eerst ingediend

13 maart 2024

Eerst ingediend dat voldeed aan de QC-criteria

13 maart 2024

Eerst geplaatst (Werkelijk)

20 maart 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • STUDY00007230
  • U54CK000601 (Subsidie/contract van de Amerikaanse NIH)
  • 2024P008055 (Andere identificatie: Emory IRB)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Deidentified participant solicited adverse event and serious adverse event data will be shared.

Isolate genomic data and participant metagenomic data will be shared in public repositories (NCBI) at time of publication

IPD-tijdsbestek voor delen

Data will become available at time of publication.

IPD-toegangscriteria voor delen

Sequence data access will not be restricted. Additional participant-level data will be shared by review of PI of proposing investigators and appropriate ethical approval (e.g. IRB) if any.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren